Displaying results 1 - 4 of 4
Clear search
Proposed Delisting via Merger of BenevolentAI into Osaka Holdings S.à r.l. and Publication of Notice of Extraordinary General Meeting
London, UK, 6 February 2025: BenevolentAI, (“BenevolentAI” or “the Company”) (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, announces:
BenevolentAI appoints Dr. Joerg Moeller as Chief Executive Officer
An accomplished R&D leader and champion of the application of AI to drug discovery.
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter the Company’s portfolio.
BenevolentAI raises $115 million to extend global position in AI enabled drug development
BenevolentAI announced that it has raised $115 million from new and existing investors at a pre-money valuation of $2 billion in one of the largest funding rounds in the AI pharmaceutical sector.